Sagimet Biosciences (SGMT) Cash from Operations (2022 - 2026)

Sagimet Biosciences' Cash from Operations history runs 5 years deep, the most recent figure standing at 8611000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 40.76% year-over-year to 8611000.0; the TTM figure through Mar 2026 stood at 39725000.0 (up 21.74% YoY), while the FY2025 annual figure was 45650000.0, down 7.58% from the prior year.
• Cash from Operations was 8611000.0 for Q1 2026 at Sagimet Biosciences, up from 11833000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 3000.0 in Q2 2022 to a low of 19569000.0 in Q3 2024.
• Historically, Cash from Operations has averaged 8384500.0 across 5 years, with a median of 7287000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 190566.67% in 2023, then surged 47.98% in 2025.
• A 5-year view of Cash from Operations shows it stood at 7490000.0 in 2022, then grew by 5.43% to 7083000.0 in 2023, then tumbled by 55.64% to 11024000.0 in 2024, then retreated by 7.34% to 11833000.0 in 2025, then gained by 27.23% to 8611000.0 in 2026.
• The last three Cash from Operations figures came in at 8611000.0 (Q1 2026), 11833000.0 (Q4 2025), and 10180000.0 (Q3 2025), per Business Quant data.